“There remains a significant unmet need for novel treatment advances to ensure greater sustained responses and improve survival for patients with advanced colorectal cancer,” said Johanna Bendell, study investigator and director of GI Cancer Research Program at Sarah Cannon Research Institute. “This underscores that targeting cancer stemness may suppress cancer relapse and metastasis.”
In a second phase 2 study, napabucasin further impressed when combined with panitumumab – an antibody drug used to treat CRC. Napabucasin demonstrated anti-cancer activity in metastatic CRC patients with K-ras mutations (a type of mutation known to greatly reduce the anti-cancer effect of panitumumab) when combined with panitumumab.
The results suggest napabucasin may re-sensitise metastatic CRC to panitumumab treatment.